Navigation Links
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Date:2/19/2009

care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion worldwide.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to ob
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...   3D Systems   (NYSE: DDD ) ... , a new robotic surgery skills and procedural training simulator, ... ERUS exhibition in Amsterdam, The Netherlands ... minimally invasive surgery represents a growing portion of overall surgical ... for robotic surgery has increased, and it is expected that ...
(Date:9/18/2014)...  Neurotrope, Inc. (OTCQB: NTRP) today announced the appointment ... the Company,s Board of Directors, effective September 12, 2014. ... the Board of seven members. Dr. Altstiel will also ... and a member of the Audit and Compensation Committees ... Scientific Advisory Board, a position he has held since ...
(Date:9/18/2014)... , Sept. 18, 2014 Australian biomarker discovery ... US trial of its MiStat™ prostate cancer screening test, ... regulatory approval upon completion. Minomic,s proprietary MiStat™ ... presence of a proprietary biomarker known as the MIL-38 ... prostate cancer cells. Researchers at 11 ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... EATONTOWN, N.J. , Jan. 14 Osteotech, Inc. (Nasdaq: ... products for regenerative healing, today reported preliminary unaudited revenue for the ... $24.6 million for the same period in 2008.  During ... revenue from sales of its new innovative products all currently in ...
... and NORTH BRUNSWICK, N.J. , Jan. 14 ... that they have achieved the initial milestone of a research ... vitro test for potential allergic reactions to substances that could ... "Allergy Test on a Chip™," is intended to comprise a ...
Cached Medicine Technology:Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 2Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 3Osteotech Announces Preliminary Fourth Quarter 2009 Revenue 4L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 2L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip 3
(Date:9/18/2014)... is good for you. But new research from University ... added benefit for cancer patients undergoing chemotherapy. , Their ... that combining exercise with chemotherapy shrunk tumors more than ... in the School of Nursing and director of the ... senior author on the study, which appears in the ...
(Date:9/18/2014)... September 18, 2014 TayganPoint Consulting ... today that President and co-founder John Cassimatis was ... Award Winners for 2014, recognizing the region’s top ... an emerging executive of the year. , The ... life sciences that continue to shape the medical ...
(Date:9/18/2014)... September 18, 2014 Ben Quirk, CEO ... Ormond, Jr. Leadership Award by the Savannah Science Seminar ... and wellness throughout the nation and especially in Savannah. ... award,” said Ben. “The Savannah Science Seminar is an ... and multiple generations have gone through the program,” he ...
(Date:9/18/2014)... new method to study Ebola virus in wildlife. Video ... (WCS)-led research, published today in the journal PLOS ... samples from wild great apes to identify populations likely ... a new tool for performing large, population-scale field assessments ... studied and improve our understanding of the virus, distribution ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded the ... grant to the Los Angeles Biomedical Research Institute (LA ... a vaccine to protect patients from the healthcare-related infections, ... (MRSA). , The National Institute of Allergy and ... to LA BioMed infectious disease specialists John E. Edwards, ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... ITASCA, Ill., March 20 Arthur J. ... Healthcare Risk Solutions, LLC,headquartered in Fort Washington, ... Founded in 2002, Healthcare Risk Solutions, ... professional liability insurance,products, associated risk mitigation consulting ...
... PRGO ; TASE) today announced that the ... Jersey has denied Connetics Corporation,s motion,for a preliminary ... generic equivalent to Connetics, Olux(R) Foam and has,lifted ... launching,the product. The Court also denied Perrigo,s motion ...
... emotional well-being, study suggests , , THURSDAY, March 20 (HealthDay ... health of the husband -- as either patient or ... of mind, new research suggests. , The finding suggests ... his wife,s experience of psychological distress more so than ...
... WASHINGTON, March 20 Veterans in seven,additional states ... Department of Veterans Affairs (VA) plan to open 14 ... James B. Peake today,announced that VA will establish new ... "VA is dedicated to providing the best in ...
... was a rainy,Saturday, nothing could dampen the spirits ... Free Families (DCTFF) hosted a special evening at,Saturday,s ... over 100 D.C.,residents who have quit smoking using ... Health Care, Inc., (Photo: http://www.newscom.com/cgi-bin/prnh/20080320/NETH063 ...
... halve by 2015 the number of people without toilet access ... every dollar spent installing toilets in developing countries, there would ... according to a UN report released today. , The UN ... 2015 the number of people worldwide who don,t have access ...
Cached Medicine News:Health News:Perrigo Company Announces Launch of Clobetasol Propionate Foam 2Health News:Perrigo Company Announces Launch of Clobetasol Propionate Foam 3Health News:Cancer Poses Challenges for Husbands' Frame of Mind 2Health News:Cancer Poses Challenges for Husbands' Frame of Mind 3Health News:VA to Open 14 New Clinics in Seven States 2Health News:Quitters Honored at Wizards' DC Tobacco Free Family Night 2Health News:Cleaning Up the World's Sanitation 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: